Background: Renal artery stenosis (RAS) is always associated with abnormalities in renal microvascular perfusion (RMP). However, few imaging methods can simultaneously evaluate the degree of luminal stenosis and RMP. Thus, this study will aim to evaluate the feasibility of using contrast-enhanced ultrasound (CEUS) for assessing both RAS and RMP to achieve a one-stop assessment of patients with suspected renovascular hypertension.
Introduction
Renal artery stenosis (RAS) is a common condition with a poor prognosis. Atherosclerosis accounts for nearly 90% of RAS in older persons and it usually involves the ostium and proximal third of the main renal artery and the perirenal aorta. [1] RAS is associated with increased risk of renal microvascular perfusion (RMP) abnormalities. Renal cortical perfusion dysfunction becomes significant even at a RAS around 30%. [2, 3] Moreover, compared with patients with hypertension and patent renal arteries, those with hypertension and low-grade stenosis have been shown to have markedly faster decline in renal function and to be at higher risk of cardiovascular complications. [4] Kalra et al [5] have shown that, compared with the general population, incident RAS that has developed in individuals without renovascular disease is associated with a markedly increased risk of cardiovascular complications and mortality. Therefore, one-stop evaluation of RAS and RMP in patients with suspected renovascular hypertension is warranted.
Conventional imaging techniques are suboptimal for 1-stop assessment for RAS and RMP. Contrast-enhanced computed tomography (CT) renal angiography (CTA) and CT perfusion imaging is commonly used to evaluate RAS and RMP simultaneously. [6] Additionally, with technological advances, MR angiography and dynamic MR techniques for measuring renal perfusion are also being used to assess RAS and RMP. [7] However, these methods often require intravenous injection of contrast agents, which are hazard in patients with renal insufficiency, [8] rendering them dangerous in patients with Stages 4 and 5 chronic kidney disease (CKD). Furthermore, radionuclide methods involve exposure to radioactivity. [9] Therefore, a safe and effective 1-stop method for evaluating RAS and RMP is needed.
Contrast-enhanced ultrasound (CEUS) is a reliable and non-invasive imaging method for assessing RAS and RMP. Many studies have confirmed that CEUS is a safe and accurate means for evaluating the degree of stenosis and RMP. [10, 11] However, there are few prior studies on investigating the feasibility of CEUS in patients with renovascular hypertension. Hence, we plan to perform this study to evaluate the safety and feasibility of CEUS for evaluating RAS and RMP.
Methods

Ethical approval
The present study will be conducted in Beijing in China, and be in accordance with the guiding principles for human experimentation summarized in the latest version of the Declaration of Helsinki. The study protocol has been approved by the Institutional Review Board (IRB) of Beijing Hospital (No. 2018BJYYEC-043-02), and will meet regularly and monitor the progress of this study. Informed consent will be obtained from all participants.
Study design
This will be a single-center diagnostic study. First, all patients with suspected resistant hypertension will undergo CEUS and CTA. Based on the stenotic degree of luminal diameter, RAS is divided into low-grade (lumen reduced by <60%) and high-grade (lumen reduced by ≥60%) stenosis. [12] Thus, the diagnostic value of CEUS for low and high-grade RAS will be compared with CTA. Second, all patients will undergo CEUS and radionuclide imaging, and associations between RMP variables evaluated by CEUS and glomerular filtration rate (GFR) measured by radionuclide methods will be analyzed to find the optimal RMP variable associated with GFR. Therefore, CEUS with 1-stop strategy will constitute assessment of RAS and RMP simultaneously.
Study organization
This study has been designed by a team of researchers from an external institution, National Center of Gerontology, Beijing Hospital. It will be conducted in 3 Departments, those of Cardiology, Nephrology, and Vascular Disease, in the authors' institution. The Executive Committee includes a project manager, research physicians/investigators, and research coordinators. The project manager will review all case report forms to ensure that enrolment criteria have been met, the protocol has been correctly implemented, and reports are accurate each week after enrolment. All investigators and study staff are required to attend a site training to explain the protocol before the study is initiated.
Participants
Adult patients (age ≥18 years old) of both sexes with suspected renovascular hypertension will be assessed for eligibility according to the following inclusion and exclusion criteria.
Inclusion criteria
Patients suspected of resistant hypertension will be included in this study. [13, 14] Eligibility requires meeting of one of the following criteria: (1) onset of hypertension before the age of 30 years or severe hypertension and age >55 years; (2) resistant, malignant, or accelerated hypertension; (3) development of new azotemia or worsening renal function after administration of an angiotensin converting enzyme inhibitor or angiotensin receptor blocker; (4) unexplained atrophic kidney or size discrepancy between kidneys of >1.5 cm; (5) unexplained renal dysfunction; (6) sudden, unexplained pulmonary edema; (7) abdominal vascular bruits; (8) hypokalemia; or (9) other vascular diseases such as peripheral arterial disease.
Exclusion criteria
Individuals who met any of the following exclusion criteria will be excluded from this study: (1) severe heart and/or pulmonary dysfunction; (2) sensitive to sulfur hexafluoride and/or iodinated contrast agent; (3) pregnancy; (4) coexisting cancer; or (5) poor images.
Study procedures
All participants will be identified by inpatient services of the 3 participating wards. A research physician will confirm the diagnosis of RAS by CTA and the GFR by a radionuclide imaging method. The one-stop strategy will constitute assessment of RAS followed by evaluation of RCP with CEUS.
The CEUS will be performed with the patient in a supine and/or left or right lateral position, depending on which artery is being assessed. All assessments will be performed by 3 operators (Ren JH, Ma N and Wang SY), using a high-resolution ultrasonograph (GE LOGIQ E8 with a 3.5-5 MHz electronic probe) and an intravenous contrast galactose microparticle suspension containing microbubbles (SF6; Sono Vue, Bracco, Milan, Italy). An injectable preparation of 5 mL of a suspension of Sono Vue will be administered by bolus injection (1.25 mL for each kidney). The Sono Vue will provide amplification of the Doppler signal for 5 min from starting the bolus. RAS will be diagnosed in accordance with the indirect or direct criteria [ Table 1 ]. RMP variables will be analyzed using specialized computer software Sonoliver ® (TomTec Imaging Systems, Germany) that generates time-dependent intensity curves on selected regions of interest in the renal cortex. Peak intensity (PI), time-to-peak intensity (TTP), mean transit time (MTT), and area under the curve (AUC) will be the key observational variables for renal RMP [ Figure 1] . CEUS images will be independently reviewed by 2 radiologists who will be blinding to the study.
Data collection
Data will be collected via abstraction from central medical charts, physical examinations, and laboratory tests. Standardized instruments will be used. All data will be treated as protected health information and securely stored in a password-protected database.
Study outcomes
The primary outcome is the diagnostic value of CEUS compared with CTA for low-grade (lumen reduced by <60%) and high-grade (lumen reduced by ≥60%) RAS, [12] including (1) positive predictive value (PPV); (2) negative predictive value (NPV); (3) sensitivity; (4) specificity; (5) accuracy; and (6) area under the receiver operating characteristic curve.
The secondary outcome is the association between CEUS findings for RMP and GFR measured by a radionuclide imaging method. These variables will include PI, rise time (RT), TTP, MTT, AUC.
Safety end points are the risks of local or systemic adverse events associated with planned imaging methods, including the number (percentage) of patients having allergic reactions, palpitation, dizziness, and contrast-induced nephropathy (CIN). [15] CIN will be diagnosed if all 4 of the following criteria are met: (1) exposure to contrast agent; (2) increase in serum creatinine concentration of 0.5 mg/dL or 25% greater than baseline; (3) increase in serum creatinine concentration occurring 48-72 h after administration of contrast agent and persisting for 2-5 d; and (4) exclusion of alternative major responsible factors. Any new condition (symptom, injury, or significant abnormal laboratory value) that is not present at the beginning of the study will be documented as an unexpected adverse event. Serious adverse events, including D-MRA: diameter at the main renal artery; D-SRS: diameter at the stenotic renal artery; PSV-A: peak systolic velocity of the abdominal aorta; PSV-P: peak systolic velocity at the proximal main renal artery; RAR: renal aortic ratio PSV-P/PSV-A: lesion divided by the diameter at the normal renal artery; NA: not avaliable. Chinese Medical Journal 2019;132 (1) www.cmj.org death, life-threatening events, hospitalization or prolongation of hospitalization, requirement of medical/surgical intervention, and CIN, will be reported to the Institutional Review Board (IRB) within 24 h.
Statistical analysis
In this diagnostic study, categorical variables will be compared. In accordance with the previous studies, [16, 17] the hypothetical sensitivity is 0.85 and specificity is 0.9, and acceptable variations in sensitivity and specificity both is 0.05. With a as 0.05, 2-tailed test, and accuracy as 0.5, the minimal required sample size is 400. If the attrition rate can be kept at 1 higher than 0.1, a sample size of 440 should be adequate.
Results will be analyzed quantitatively with STATA 14.0 software (Stata, CA). Continuous variables will be expressed as mean ± standard deviation (SD), and categorical variables expressed as frequencies or percentages. Categorical variables will be compared using the x 2 or Fisher's exact test and quantitative variables using the paired samples t-test. The diagnostic value for RAS will be assessed by the receiver operating characteristic curve, including the accuracy, sensitivity, specificity, PPVs, NPVs, and AUC. Pearson correlation analysis will be performed to assess the association between CEUS findings for RMP and GFR measured by a radionuclide imaging method. Statistical significance will be set at 0.05.
Discussion
This will be a single-center diagnostic study aimed at investigating the feasibility, safety, and accuracy of CEUS for 1-stop assessment of RAS and RMP in patients with suspected renovascular hypertension. The study will provide evidence as to whether CEUS can safely and reliably provide clinical benefits with respect to simultaneous evaluation of RAS and RMP, especially in patients with renal insufficiency.
The CEUS is a reliable imaging method to assess the functional significance of RAS. What extent a kidney is influenced depends on not only the degree of the stenosis, but also how acutely this happens, and the autoregulatory potential of the kidney. Real-time CEUS using microbubble-based contrast agents, which are well regarded for the renal safety, high tolerance, and lack of radiation, can visualize the perfused microvascular bed. Kogan et al [18] found that CEUS-derived parameters, such as PI, TTP, MTT, and area under the time-dependent intensity curve, were comparable to absolute measurements of blood flow in rat kidney. In humans, CEUS has already been used to the study of various kidney diseases, including acute kidney injury, [19] CKD, [20] and kidney transplantation. [21] By assessing RMP, CEUS could not only evaluate renal dysfunction, but also predict early kidney injury. [22] Furthermore, several clinical studies have showed that angioplasty with or without stenting could not decrease the level of systolic blood pressure, the rate of renal events and cardiovascular complications in patients with high-grade stenosis. [23] [24] [25] However, the included patients were with high-grade stenosis, had little viable kidney tissue left, and their chances to improve after revascularization were poor. [26] Therefore, CEUS may be useful to guide the patient selection and efficacy evaluation in angioplasty procedure. Collectively, CEUS can provide real-time, noninvasive, and relative quantitative estimate of RMP and offers great potential in monitoring and predicting renal injury in acute and chronic renal disease. However, there is no international standard for assessing RMP. Hence, wellpowered clinical studies are needed to establish the parameters that are optimal for clinical evaluation and the normal range in different patient groups.
This study could make several important contributions to expanding clinical applications of CEUS in patients with suspected renovascular hypertension. First, this study will provide preliminary evidence of the accuracy of CEUS for RAS in real-world practice, especially in patients with lowgrade stenosis. Second, this study will provide evidence concerning the safety of CEUS, especially in patients with Stages 4 and 5 CKD. Third, this study will promote the clinical application of CEUS for assessment of renal RMP. Real-time CEUS using microbubble-based contrast agents, which are well regarded for their renal safety, high tolerance, and lack of radiation, enable visualization of the perfused microvascular bed. [27] Thus, CEUS can provide real-time, non-invasive, [28] and relative quantitative estimate of renal RMP and offers great potential for monitoring and prediction of renal injury in acute and chronic renal disease. [29] 
Study limitations
The present study has a few limitations. First, this study was a single-center design, therefore, it cannot represent the actual situation of the whole RAS population owing to geographical and regional differences. Second, there are inherent limitations to use an observational method owing to these unmeasured or undefined confounding factors. Third, there is no international standard for assessing RMP, and the normal range in different patient groups is also lacking. Fourth, CEUS is operator dependent. Previous study showed that imaging quality was correlated with the radiologist's experience, and it was markedly higher for radiologists who had performed more than 60 CEUS examination. [30] Fifth, CEUS has an inherent relatively high variability, related to several factors, including the patient, contrast agent used, and machine settings. Stock et al [31] found that time-related parameters for the renal cortex showed a reasonable repeatability, whereas poor repeatability is present for intensitity-related parameters and those related to inflow and outflow of contrast agent. Furthermore, Lassau et al [32] showed that AUC and area under the washout are the 2 most reproducible CEUS parameters. Therefore, future studies will require larger numbers of patients, careful matching of key clinical and technical variables to definitively quantify the potential clinical value of one-stop evaluation of RAS and RMP by CEUS for patients with suspected RAS.
In summary, we have designed this study to evaluate the feasibility, safety, and accuracy of CEUS for 1-stop assessment of RAS and RMP in patients with resistant hypertension.
